Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Must have received:

DLBCL: relapsed after, or was refractory to, at least 2 prior lines of therapy

Must have received:

FL: relapsed after, or was refractory to, at least 1 prior systemic therapy

Must have received:

MZL: relapsed after, or was refractory to, at least 1 prior therapy

Must have received:

MCL: relapsed after, or was refractory to, at least 1 prior systemic therapy

Must have received:

CLL/SLL: previously untreated and/or relapsed/refractory CLL defined as disease that relapsed after, or was refractory to, at least 1 prior therapy will be included

Cannot have received: autologous stem cell transplant

Exception: allowed if ≥ 30 days after transplant

Prior autologous stem cell transplant unless ≥ 30 days after transplant

Cannot have received: chimeric antigen receptor T cell therapy

Exception: allowed if ≥ 30 days after cell infusion

prior chimeric antigen receptor T cell (CAR-T) therapy unless ≥ 30 days after cell infusion

Cannot have received: allogeneic stem cell transplant

Exception: excluded if active GVHD, or requiring immunosuppressive drugs for GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent

Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent

Cannot have received: BCL2 inhibitor (venetoclax)

Exception: excluded if prior therapy ≥ 2 months with or progression on a Bcl2 inhibitor

Prior therapy ≥ 2 months with or progression on a Bcl2 inhibitor (eg, venetoclax)

Cannot have received: biologic and/or immunologic-based therapy (rituximab)

Exception: excluded if within 28 days before first dose

≤ 28 days before first dose of study drug: Any biologic and/or immunologic-based therapy(ies) including experimental therapy(ies) for leukemia, lymphoma, or myeloma (including, but not limited to, monoclonal antibody therapy, eg, rituximab, and/or cancer vaccine therapy)

Cannot have received: systemic chemotherapy

Exception: excluded if within 14 days before first dose

≤ 14 days before the first dose of study drug: systemic chemotherapy or radiation therapy

Cannot have received: radiation therapy

Exception: excluded if within 14 days before first dose

≤ 14 days before the first dose of study drug: systemic chemotherapy or radiation therapy

Cannot have received: corticosteroid

Exception: excluded if within 7 days before first dose, unless for control of BTK inhibitor withdrawal flare

≤ 7 days before the first dose of study drug: corticosteroid given with antineoplastic intent other than control of BTK inhibitor withdrawal flare

Cannot have received: BTK inhibitor

Exception: excluded if within 5 half-lives before first dose

≤ 5 half-lives before the first dose of study drug: BTK inhibitor, tyrosine kinase inhibitor, or other targeted small molecule given with antineoplastic intent

Cannot have received: tyrosine kinase inhibitor

Exception: excluded if within 5 half-lives before first dose

≤ 5 half-lives before the first dose of study drug: BTK inhibitor, tyrosine kinase inhibitor, or other targeted small molecule given with antineoplastic intent

Cannot have received: targeted small molecule

Exception: excluded if within 5 half-lives before first dose

≤ 5 half-lives before the first dose of study drug: BTK inhibitor, tyrosine kinase inhibitor, or other targeted small molecule given with antineoplastic intent